Copyright
©The Author(s) 2015.
World J Gastrointest Pharmacol Ther. May 6, 2015; 6(2): 17-21
Published online May 6, 2015. doi: 10.4292/wjgpt.v6.i2.17
Published online May 6, 2015. doi: 10.4292/wjgpt.v6.i2.17
Table 2 Polymorphisms that potentially affect the antiplatelet effect of clopidogrel
| Polymorphism | Mechanism of reduced antiplatelet effect of clopidogrel |
| CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*7, CYP2C19*8 | Reduced metabolism of clopidogrel to its active metabolite |
| C3435T polymorphism of the ABCB1 gene | Overexpression of the drug efflux pump P-glycoprotein leading to reduced intestinal absorption of clopidogrel |
| Q192R polymorphism of the paraoxonase-1 gene | Reduced metabolism of clopidogrel to its active metabolite |
- Citation: Bouziana SD, Tziomalos K. Clinical relevance of clopidogrel-proton pump inhibitors interaction. World J Gastrointest Pharmacol Ther 2015; 6(2): 17-21
- URL: https://www.wjgnet.com/2150-5349/full/v6/i2/17.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v6.i2.17